Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.
The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already…